Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 4;17(2):e0263375.
doi: 10.1371/journal.pone.0263375. eCollection 2022.

Acceptance rate and risk perception towards the COVID-19 vaccine in Botswana

Lebapotswe B Tlale  1 , Lesego Gabaitiri  2 , Lorato K Totolo  1 , Gomolemo Smith  1 , Orapeleng Puswane-Katse  1 , Eunice Ramonna  1 , Basego Mothowaeng  1 , John Tlhakanelo  2 , Tiny Masupe  2 , Goabaone Rankgoane-Pono  1 , John Irige  3 , Faith Mafa  1 , Samuel Kolane  1
Affiliations

Acceptance rate and risk perception towards the COVID-19 vaccine in Botswana

Lebapotswe B Tlale et al. PLoS One. .

Abstract

Background: The COVID-19 disease burden continues to be high worldwide and vaccines continue to be developed to help combat the pandemic. Acceptance and risk perception for COVID-19 vaccines is unknown in Botswana despite the government's decision to roll out the vaccine nationally.

Objectives: This study aims to assess the acceptance rate and risk perception of COVID-19 vaccines amongst the general population in Botswana.

Methods: We interviewed 5300 adults in Botswana from 1-28 February 2021 using self-administered questionnaires. The main outcomes of the study were vaccine acceptance and hesitancy rates. Demographic, experiential and socio-cultural factors were explored for their association with outcome variables.

Results: Two-thirds of the participants were females (3199), with those aged 24-54 making the highest proportion (61%). The acceptance rate of COVID-19 vaccine was 73.4% (95% CI: 72.2%-74.6%) with vaccine hesitancy at 31.3% (95% CI: 30.0%-32.6%). When the dependent variable was vaccine acceptance, males had higher odds of accepting the vaccine compared to females (OR = 1.2, 95% CI: 1.0, 1.4). Individuals aged 55-64 had high odds of accepting the vaccine compared to those aged 65 and above (OR = 1.2, 95% CI: 0.6, 2.5). The odds of accepting the vaccine for someone with primary school education were about 2.5 times that of an individual with post graduate level of education. Finally, individuals with comorbidities had higher odds (OR = 1.2, 95% CI: 1.0, 1.5) of accepting the vaccine compared to those without any underlying conditions.

Conclusion: This study demonstrated a high acceptance rate for the COVID-19 vaccine and a low risk perception in Botswana. In order to achieve a high vaccine coverage and ensure a successful vaccination process, there is need to target populations with high vaccine hesitancy rates. A qualitative study to assess the factors associated with vaccine acceptance and hesitancy is recommended to provide an in-depth analysis of the findings.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Vaccine safety.
See this image and copyright information in PMC

References

    1. World Health Organisation. COVID-19 Weekly Epidemiological Update. 14 February 2021. The World Health Organisation.
    1. Al-Mohathithef M and Phadi B, Determinants of Vaccine Acceptance in Saudi Arabia: A Web-Based National Survey. https://www.dovepress.com/journal-of-multidisciplinary-healthcare-journal. - PMC - PubMed
    1. Saha RP, Sharma AR, Singh MK, et al.. Repurposing drugs, ongoing vaccine, and new therapeutic development initiatives against COVID-19. Front Pharmacol. 2020;11. doi: 10.3389/fphar.2020.00011 - DOI - PMC - PubMed
    1. Chakraborty C, Sharma AR, Sharma G, Bhattacharya M, Saha RP, Lee -S-S. Extensive partnership, collaboration, and teamwork is required to stop the COVID-19 outbreak. Arch Med Res. 2020;51(7):728–730. doi: 10.1016/j.arcmed.2020.05.021 - DOI - PMC - PubMed
    1. Bhattacharya M, Sharma AR, Patra P, et al.. Development of epitope‐based peptide vaccine against novel coronavirus 2019 (SARS‐COV‐2): immunoinformatics approach. J Med Virol. 2020;92(6):618–631. doi: 10.1002/jmv.25736 - DOI - PMC - PubMed

MeSH terms

Substances